Impact of Hepatitis B Vaccination on HBs Antigenemia
Primary Purpose
HBV
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
HBV vaccine
Sponsored by
About this trial
This is an interventional treatment trial for HBV focused on measuring HBV vaccine, persistent, HBsAg, IP-10
Eligibility Criteria
Inclusion Criteria:
- HBV patients with persistent HBs antigenemia
Exclusion Criteria:
- decompensated liver cirrhosis
- hepatocellular carcinoma
- other causes of liver disease or mixed causes (excessive alcohol consumption,
- autoimmune liver disease
- immunosuppressive drugs
- infection with hepatitis C virus.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
No Intervention
Arm Label
chronic HBV with persistent HBsAg
control group
Arm Description
inactive carriers (n=100). Group II: CHB exposed to nucleos(t)ides (n=120) till 6 months after HBe seroconversion and HBV DNA disappearance in HBeAg positive (n=60) or DNA disappearance in HBeAg negative patients (n=60). All showed persistent HBs antigenemia. they were given 30 µg of HBV vaccine initiated 6 months after HBe seroconversion and disappearance of HBV DNA.
A control group (n=100) did not receive HBV vaccine
Outcomes
Primary Outcome Measures
production of protective HBsAb
Current treatment by NAs may suppress HBV replication but cannot completely eradicate the virus due to the systemic immune tolerance or exhaustion. HBV vaccine may enhance the immunity against HBsAg and may be an efficient immunotherapy in chronic HBV.
Secondary Outcome Measures
impact on Insulin resistance, fibrosis regression
study of the possibility of improving insulin resistance and degree of fibrosis
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03193775
Brief Title
Impact of Hepatitis B Vaccination on HBs Antigenemia
Official Title
Impact of Hepatitis B Vaccination on HBsAg Kinetics, Interferon-inducible Protein 10 Level and Recurrence of Viremia
Study Type
Interventional
2. Study Status
Record Verification Date
June 2017
Overall Recruitment Status
Completed
Study Start Date
August 1, 2011 (Actual)
Primary Completion Date
October 1, 2015 (Actual)
Study Completion Date
October 1, 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Zagazig University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
HBV is not curable with persistent HBsAg even after the disappearance of HBV DNA.
HBsAg > 1000 IU/ml is associated with the risk of virological recurrence and HCC.
There is an impaired immune response to HBsAg and HBV vaccine is an easily available, cost-effective, non-harmful method of stimulating immunity.
Detailed Description
Persistent HBs antigenemia >1000 IU/ml has a possibility of viral reactivation and hepatoma in 8%; the effect of HBV vaccine on HBsAg was investigated, recurrence of viremia, insulin resistance, and fibrosis regression.
From August 2011 to October 2016, 220 participants with chronic hepatitis B were evaluated at the hepatology clinic-Internal medicine department-Zagazig university-Egypt. They were enrolled after approval of the ethical committee of Zagazig university hospital. Written informed consent was obtained for the interview, clinical evaluation, and blood sampling.
participants were divided into two groups:
Inactive carriers (n=100) who were presented with persistent HBsAg, undetected HBV DNA, normal liver enzymes, positive HBeAb and had never been exposed to antiviral therapy.
Patients exposed to NAs (n=120): tenofovir 300mg (n=65) or Entecavir 1mg (n=55): A- HBeAg-positive patients (n=60) who received NAs until 1 year after HBe seroconversion and disappearance of HBV DNA with persistent HBsAg B- HBeAg-negative patients (n=60) who received NAs till 3 years after the disappearance of HBV DNA; all showed persistent HBsAg.
Exclusion criteria Clinically decompensated liver cirrhosis; hepatocellular carcinoma; other causes of liver disease or mixed causes (excessive alcohol consumption, autoimmune liver disease, immunosuppressive drugs, or who had been infected with hepatitis C virus.
B- Vaccination schedule
All the participants had received 30 µg of recombinant HBV vaccine which contains Purified HBsAg produced by recombinant DNA technology (Euvax-B, LG Life Sciences, Korea) intramuscularly in the deltoid region at three different time intervals (0, 1, 6 months). The first dose of the vaccine was initiated 1 year after HBe seroconversion and disappearance of HBV DNA in HBe +ve or 3 years after the disappearance of HBV DNA in HBe -ve patients or immediately after diagnosis of inactive carriers. NAs were stopped three months after the 3rd dose of HBV vaccine
Three months after the last dose of vaccine, the participants were evaluated for IP-10 level, the production of protective HBsAb, recurrence of viremia by regular HBV DNA, HBsAg quantification.
Patients who failed to produce HBsAb i.e. HBsAb titer < 10 IU/ml, were given a fourth booster dose of vaccination immediately after confirmation of vaccine non-response.
C- Control Group It included 100 participants who had CHB, with undetectable HBV DNA with persistence of HBsAg and they did not receive HBV vaccine. They were divided into treatment naïve (n=50) and treatment experienced (n=50) who were given tenofovir (n=30) or entecavir (n=20) which were stopped 3 years after HBV DNA disappearance and HBeAg seroconversion and followed for 3 years by evaluation of HBsAg level and HBV DNA every 6 months to detect the natural rate of HBV reactivation.
D- Laboratory analysis It included complete Blood Count, liver function tests, prothrombin time, prothrombin concentration (%), kidney function tests.
HCV antibody, HBeAg, HBeAb, HBcAb.
Real-time Quantitative PCR for HBV DNA was done at the baseline and then every 6 months after the last dose of HBV vaccine for 3 years (COBAS AMPLICOR HBV MONITOR, with a detection limit of 15 IU/ml; Roche Diagnostic Systems).
Insulin resistance was done before initiation of vaccination and 3 months after the last dose of vaccination. It was calculated by HOMA-IR, a value greater than 2 indicates insulin resistance [20].
HBV genotyping was performed using INNO-LiPA HBV Genotyping assay; Innogenetics NV, Ghent, Belgium.
Determination of HBsAg titer (Elecsys HBsAg II assay, Roche Diagnostics, USA) [21]. It was done before vaccination and 3 months after the last dose of vaccine then every 6 months for 3 years.
Anti-HBs antibodies were performed 3 months following the third dose of the vaccine or 3 months after the 4th booster dose. Seroconversion was considered if anti-HBs levels were above 10 IU/ml and non-response if anti-HBs levels were below 10 IU/ml [22].
Serum IP-10 levels were determined in serum before vaccination and 3 months after the last dose of vaccine, by a solid-phase sandwich ELISA (Quantikine, R&D Systems, USA) (reference value: 7.8-500 pg/ml).
E- Abdominal ultrasonography participants were examined after 6 hours fast. Criteria of cirrhosis, portal hypertension, and the presence of fatty liver disease were documented.
F- Liver stiffness assessment (LSM) Fibroscan was performed to measure liver stiffness before antiviral therapy and 3 months after the last dose of HBV vaccine, with the number of shots is 10, interquartile range≤ 25%. Liver stiffness 2.5-7 kPa denotes (F0-1), 7-9.5 kPa (F2), 9.5-12.5 kPa (F3), >12.5 kPa denotes cirrhosis.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HBV
Keywords
HBV vaccine, persistent, HBsAg, IP-10
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Group I: inactive carriers (n=100). Group II: CHB exposed to nucleos(t)ides (n=120) till 6 months after HBe seroconversion and HBV DNA disappearance in HBeAg positive (n=60) or DNA disappearance in HBeAg negative patients (n=60). All showed persistent HBs antigenemia.
-A control group (n=100) did not receive HBV vaccine
Masking
None (Open Label)
Masking Description
open label
Allocation
Randomized
Enrollment
220 (Actual)
8. Arms, Groups, and Interventions
Arm Title
chronic HBV with persistent HBsAg
Arm Type
Active Comparator
Arm Description
inactive carriers (n=100). Group II: CHB exposed to nucleos(t)ides (n=120) till 6 months after HBe seroconversion and HBV DNA disappearance in HBeAg positive (n=60) or DNA disappearance in HBeAg negative patients (n=60). All showed persistent HBs antigenemia.
they were given 30 µg of HBV vaccine initiated 6 months after HBe seroconversion and disappearance of HBV DNA.
Arm Title
control group
Arm Type
No Intervention
Arm Description
A control group (n=100) did not receive HBV vaccine
Intervention Type
Biological
Intervention Name(s)
HBV vaccine
Intervention Description
HBV vaccine which contains Purified HBsAg produced by recombinant DNA technology (Euvax-B, LG Life sciences, Korea) intramuscularly in deltoid region at three different time intervals (0, 1, 6 months).
Primary Outcome Measure Information:
Title
production of protective HBsAb
Description
Current treatment by NAs may suppress HBV replication but cannot completely eradicate the virus due to the systemic immune tolerance or exhaustion. HBV vaccine may enhance the immunity against HBsAg and may be an efficient immunotherapy in chronic HBV.
Time Frame
three months after the last dose of vaccine
Secondary Outcome Measure Information:
Title
impact on Insulin resistance, fibrosis regression
Description
study of the possibility of improving insulin resistance and degree of fibrosis
Time Frame
3 month after the last dose of vaccination
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
HBV patients with persistent HBs antigenemia
Exclusion Criteria:
decompensated liver cirrhosis
hepatocellular carcinoma
other causes of liver disease or mixed causes (excessive alcohol consumption,
autoimmune liver disease
immunosuppressive drugs
infection with hepatitis C virus.
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Citations:
PubMed Identifier
28802168
Citation
Shaaban Hanafy A. Impact of hepatitis B vaccination on HBsAg kinetics, interferon-inducible protein 10 level and recurrence of viremia. Cytokine. 2017 Nov;99:99-105. doi: 10.1016/j.cyto.2017.08.002. Epub 2017 Aug 10.
Results Reference
derived
Learn more about this trial
Impact of Hepatitis B Vaccination on HBs Antigenemia
We'll reach out to this number within 24 hrs